Clinical trials: Vitiligo
Vitiligo and Acne Vulgaris
Cutaneous JAK in Vitiligo and Acne Vulgaris.
The Janus kinase/signal transducer and activator of transcription (JAK-STAT) cytokine signaling pathway is an emerging area of interest in dermatology, and emerging evidence suggests that this pathway may play a crucial role in…
- Trial name
- NCT03185312
- Testing
- skin biopsy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assiut University
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Crohn Disease, Ulcerative Colitis
Expanded Access to Upadacitinib
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis
- Trial name
- NCT04159597
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Vitiligo Vulgaris
Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo
The study is an on-line survey posted on survey monkey that addresses some demographic and environmental issues that could potentially relate to vitiligo vulgaris onset or disease exacerbation.
- Trial name
- NCT01401374
- Where
- United States
- Volunteers
- 3,258 people, healthy volunteers welcome
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Dermatologic Disease, Vitiligo
Vitiligo Registry for Adults and Children in the UK
Vitiligo is the most common depigmentation disorder affecting around 1% of the population worldwide. Fifty two percent of patients develop vitiligo before the age of 20 and around 80% develop vitiligo before the age of 30 years…
- Trial name
- VIRTUAL-UK (NCT06218082)
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Alopecia Areata, Alopecia Totalis
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
The study series consists of three studies with the aim to assess the incidence, prevalence, risk factors, comorbidities and management of patients with alopecia areata in Czech Republic based on the patients and registry of a…
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Alopecia Areata (& Ophiasis)
- Trial name
- NCT05098600
- Testing
- Exposure of interest
- Where
- Czechia
- Volunteers
- 123 people
- Sponsor
- Faculty Hospital Kralovske Vinohrady
Acceptance of Visible Chronic Dermatological Disease, Disease Acceptance
Measure of Acceptance of chRonic Visible sKin conditionS
The objective of this protocol is to validate 4 scales for evaluating the acceptance of visible chronic dermatological diseases (port wine stains, alopecia areata, vitiligo, hyperpigmentation...) with a large number of patients…
- Conditions
- Acceptance of Visible Chronic Dermatological Disease, Disease Acceptance, Psychological Well-Being, Social Segregation
- Trial name
- MARKS (NCT06103903)
- Testing
- Questionnaire
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Tours
Vitiligo
A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo
Vitiligo is a common chronic autoimmune skin disease that can occur on any part of the body and severely impacts patients' quality of life.
- Trial name
- NCT07153666
- Testing
- Ruxolitinib 1.5% Cream BID
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Peking University Third Hospital
Non Segmental Vitiligo
ICP-332 in Subjects With Non-segmental Vitiligo
This a phase II/III randomized, double-blind, placebo-controlled, parallel group, adaptive design, multi-center study to evaluate the efficacy and safety of ICP-332 in subjects with non-segmental vitiligo。The study consisted an…
- Trial name
- NCT07047612
- Testing
- ICP-332 Tablets
- Where
- 45 sites in China
- Volunteers
- 603 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Vitiligo, Generalized
Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo
The study aims to evaluate the safety and efficacy of the combination of topical baricitinib and 308-nm monochromatic excimer light versus 308-nm monochromatic excimer light alone in treatment of non-segmental vitiligo.
- Trial name
- NCT05950542
- Testing
- Baricitinib
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Assiut University
Vitiligo, Topical Fluorouracil
Topical 5-Fluorouracil Effervescent Powder in the Treatment of Vitiligo
A novel approach for 5-Fluorouracil delivery based on a solid effervescent formulation is proposed . 5-Fluorouracil is water soluble (~50mg/ml) and therefore has been used for the development of novel topical formulations…
- Conditions
- Vitiligo, Topical Fluorouracil, Effervescent Mixture
- Trial name
- NCT05536856
- Testing
- a new effervescent mixture 5-florouracil formula, 5-Fluorouracil plain powder
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Al-Azhar University
Vitiligo
Punch Minigraft Versus Transverse Needling or Combination of Both in Treatment of Non-Segmental Vitiligo
This study is to evaluate the effectiveness and tolerability of autologous punch minigraft, transverse needling technique or combination of both followed by narrow band ultraviolet B phototherapy (311 nm) in the treatment of…
- Trial name
- NCT03872804
- Testing
- Autologous punch mini grafts:, Transverse needling, Punch minigrafts followed by transverse needling
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Alexandria University
Vitiligo, Child
Oral Tacrolimus vs Dexamethasone Micro-pulse Therapy in Pediatric Rapidly Progressing Vitiligo: A Multicenter RCT
This clinical study aims to compare the safety and effectiveness of two treatments-oral Tacrolimus capsules and Dexamethasone micro-pulse therapy-in children aged 4-12 years with rapidly progressing vitiligo.
- Conditions
- Vitiligo, Child, Progressive Disease
- Trial name
- NCT06900777
- Testing
- Tacrolimus, Dexamethasone
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Xijing Hospital
Non-Segmental Vitiligo
A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental Vitiligo
Vitiligo is a common, long-lasting disease that happens when the immune system attacks melanocytes (skin cells that produce the skin-coloring pigment melanin) in the skin leading to loss of color.
- Trial name
- Ph3 Peds Viti (NCT07896434)
- Testing
- Upadacitinib
- Volunteers
- 154 people
- Sponsor
- AbbVie
Vitiligo
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV). Ritlecitinib is studied in patients with non-segmental vitiligo.
- Trial name
- Tranquillo LTE (NCT06163326)
- Testing
- Ritlecitinib, Ritlecitinib 100 mg
- Where
- 73 sites in United States, Australia and 11 more
- Volunteers
- 394 people
- Sponsor
- Pfizer
Metabolic Syndrome, Vitiligo
Metabolic Syndrome in Early Onset Versus Late Onset Vitiligo
This study aims at detection of possible associated metabolic syndrome with vitiligo and assessment of possible contribution of the age of onset of vitiligo.
- Trial name
- NCT03622320
- Testing
- Blood sample
- Where
- Egypt
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Cairo University
Serum Gasdermin D in Vitiligo
Evaluation of Serum Gasdermin D Level As a Potential Biomarker of Disease Activity in Vitiligo Patients
Assessment the serum level of Gasdermin D level in vitiligo patients. Correlate its level with disease activity scores using Vitiligo Area Severity Index (VASI) and Vitiligo Disease Activity (VIDA) scores and with different…
- Trial name
- NCT06584643
- Testing
- gasdermin d
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Assiut University
Vitiligo, Generalized
Catecholamines Level in Vitiligo Patients Before and After Excimer Light
Vitiligo is an acquired cutaneous disorder of pigmentation, with a 1-2% incidence worldwide, without predilection for sex or race.
- Trial name
- NCT04803461
- Testing
- serum and urinary catecholamines
- Volunteers
- 21 people
- Sponsor
- Assiut University
Non-Segmental Vitiligo (NSV), Alopecia Areata
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global…
- Conditions
- Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa
- Trial name
- MEASUREAAVitHS (NCT07136467)
- Where
- 116 sites in Argentina, Canada and 16 more
- Volunteers
- 2,795 people
- Sponsor
- AbbVie
Dermatologic Disease, Vitiligo
Comparison of Cyclic On-off and Continuous Excimer Laser Treatment for Vitiligo
OBJECTIVE: To investigate the efficacy of the cyclic on-off treatment compared to the conventional continuous excimer laser treatment. DESIGN: A randomized, controlled, split-body, non-inferiority study.
- Trial name
- NCT03047733
- Testing
- The XTRAC Excimer Laser System, Topical tacrolimus 0.1% ointment
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Ajou University School of Medicine